Glycerol phenylbutyrate
Brand names: Ravicti
Glycerol phenylbutyrate is a nitrogen-scavenging agent used as adjunctive long-term therapy in the management of urea cycle disorders that cannot be controlled by dietary protein restriction alone.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It is hydrolysed to phenylbutyrate and then phenylacetate, which conjugates with glutamine to form phenylacetylglutamine; this is excreted renally, providing an alternative route for waste nitrogen elimination that bypasses the deficient urea cycle.
Prescribing in practice
- It does not treat acute hyperammonaemic crises, which require emergency management; it is a long-term measure to maintain control alongside dietary protein restriction.
- It is used as part of a specialist regimen including a low-protein diet and, where appropriate, amino acid supplementation under metabolic medicine supervision.
- Reduced exposure can occur in hepatic impairment, and gastrointestinal symptoms are commonly reported.
Monitoring
Monitor plasma ammonia together with the metabolic and nutritional parameters guided by the specialist metabolic team to confirm adequate nitrogen control.
Counselling the patient
- This medicine helps control your condition long term and must be taken alongside the prescribed diet; it is not a treatment for sudden episodes.
- Do not stop or change the dose without advice from your metabolic team.
Evidence & guidelines
Nitrogen-scavenging therapy is an established component of chronic urea cycle disorder management used under specialist supervision.
Reference: SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Lower Gastrointestinal Bleed · BSG 2019; NICE NG141
- Variceal Upper GI Bleed · BSG 2015; Baveno VII (2022)
- Spontaneous Bacterial Peritonitis (SBP) · BSG / EASL 2018
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Hepatic Encephalopathy · EASL 2014; West Haven criteria
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021